In Brief
The IRGM is an established genetic risk factor for Crohn's diseases and several other inflammatory disorders. Mehto et al. show that IRGM inhibits NLRP3 inflammasome activation to keep the inflammation under check. This study provides a basis for the protective function of IRGM in inflammatory diseases.
INTRODUCTION
Acute inflammation is an essential innate immune response to self-protect from harmful stimuli, including irritants and pathogens. However, a chronic inflammatory response is deleterious and leads to several inflammatory diseases (Okin and Medzhitov, 2012) . Autophagy is a fundamental cell-survival process that plays a broad homeostatic role in cleaning cells by removing toxic wastes including determinants of surplus inflammation (Deretic et al., 2013; Ma et al., 2013) . Recently, several studies have demonstrated the importance of autophagy in protecting against chronic inflammatory diseases (Deretic and Klionsky, 2018) .
One of the most critical components of the inflammatory response are inflammasomes, which are molecular complexes that are activated by diverse danger signals of pathogenic and non-pathogenic origin, resulting in the production of the pro-inflammatory cytokines such as interleukin-1b (IL-1b) and IL-18 (Jo et al., 2016; Schroder et al., 2018) . A well-studied inflammasome is composed of the NLRP3 (NACHT, LRR, and PYD domains containing protein 3) protein that complexes with ASC (PYCARD) (apoptosis-associated speck-like protein containing a CARD) to form a caspase-1-activating complex that then cleaves and activates IL-1b (Guo et al., 2015) . Dysregulation of NLRP3 inflammasome has been linked with several chronic inflammatory, infectious, and autoimmune diseases (Lamkanfi and Dixit, 2012; Strowig et al., 2012) . Autophagy has emerged as one of the essential processes in controlling excess inflammasome activation. By mediating the degradation of obsolete mitochondria and by degrading inflammasome components including NLRP3, autophagy keeps unnecessary and aberrant activation of inflammasomes under check (Shi et al., 2012; Yan et al., 2015; Zhong et al., 2016) .
Immunity-related GTPase M (IRGM) belongs to a family of interferon-inducible GTPases (IRGs), one of the strongest cellautonomous resistance systems to intracellular pathogens (Hunn et al., 2011) . After a landmark study showing the importance of human IRGM in anti-mycobacterial autophagy (Singh et al., 2006) , several genome-wide association studies identified SNPs in the IRGM gene and a deletion polymorphism in IRGM promoter region as being strongly associated with Crohn's disease (CD) and tuberculosis (Brest et al., 2011; Che et al., 2010; McCarroll et al., 2008; Parkes et al., 2007; Wellcome Trust Case Control, 2007; Craddock et al., 2010) . Later, IRGM was genetically and functionally linked with several other chronic (A) Human colon epithelial HT-29 cells were starved (2 hr) or stimulated with LPS (100 ng/mL, 2 hr) alone or in combination with nigericin (10 mM, 1 hr) or with MDP (10 mg/mL, 6 hr), and immunoblotting was performed with lysates. (B) Human PBMCs from healthy volunteers were exposed to LPS (100 ng/mL), and total RNA was subjected to qRT-PCR using IRGM TaqMan probe. (C and D) THP-1 cells were stimulated with inflammasome inducers (C) ATP or (D) MSU crystals for the indicated time periods, and extracts were subjected to western blotting with IRGM antibody.
(legend continued on next page) inflammatory and autoimmune diseases (Baskaran et al., 2014; Burada et al., 2012; Glas et al., 2013; Yang et al., 2014) . Given the linkage of IRGM with so many inflammatory and autoimmune disorders, it is surprising that IRGM's mechanism of action in regulating inflammation remains unclear. In this study, our work reveals that human IRGM and its mice ortholog Irgm1 control inflammation by suppressing the activation of NLRP3 inflammasomes. Mechanistically, we found that IRGM physically complexes with NLRP3 inflammasome components and obstructs inflammasome assembly. IRGM interacts with SQSTM1/p62 (henceforth, p62) and mediates p62-dependent selective autophagy of NLRP3 and ASC. Thus, by restricting inflammasome activity, IRGM protects from pyroptosis. Further, we found that mouse Irgm1 suppresses the colon inflammation by inhibiting NLRP3 inflammasome in a DSS-induced colitis mouse model. Taken together, this work identifies a direct role of IRGM in suppressing the inflammation and provides a basis for its protective role in inflammatory diseases including Crohn's.
RESULTS

Human IRGM Suppresses Pro-inflammatory Cytokine Response
Human IRGM is mainly expressed in cells of myeloid and epithelial origin, and this expression is increased following exposure of interferon (IFN)-g . IRGM expression in the colon epithelial cell line HT-29 is increased under starvation conditions and by treatment of cells with the pathogen-associatedmolecular-patterns (PAMPs) such as lipopolysaccharide (LPS) and muramyl dipeptide (MDP) ( Figures 1A and S1A ). In human peripheral blood mononuclear cells (PBMCs), IRGM expression was increased on treatment with LPS ( Figure 1B) . Further, the treatment of THP-1 cells with danger-associated molecular patterns (DAMPs) such as ATP, MSU (Monosodium urate), and cholesterol crystals increased protein expression of IRGM (Figures 1C, 1D, and S1B) . The expression of IRGM was increased on infection of THP-1 cells with Salmonella typhimurium (SL1433) ( Figure S1C ). Thus, IRGM expression is induced by DAMPs, PAMPs, and microbes in innate immune cells.
Next, we investigated the role of IRGM in modulating the proinflammatory responses induced by LPS treatment and by Salmonella infection. The control and IRGM stable knockdown HT-29 human colon epithelial cells were infected with Salmonella typhimurium, and the expression of sentinel pro-inflammatory genes Il1b, Tnfa, Il18, and Rantes were monitored by qRT-PCR. As compared to the control cells, IRGM-depleted cells mounted a stronger pro-inflammatory response ( Figures 1E, 1F , S1D, and S1E). Similarly, in THP-1 cells, the LPS induced Il1b and Tnfa, expression was further increased in IRGM small interfering RNA (siRNA) knockdown cells (Figures 1G and 1H) . In these cells, Il18 expression was increased but not significantly, and Rantes expression was not affected (Figures S1F and S1G). Further, human PBMCs from healthy donors showed enhanced production of pro-inflammatory cytokine Il1b and Tnfa when IRGM was knockdown ( Figures 1I and 1J ). Furthermore, the secretion of IL-6 and tumor necrosis factor alpha (TNF-a) was significantly higher in IRGM-depleted THP-1 cells as compared to the control cells (Figures S1H and S1I). Taken together, the data suggest that IRGM suppresses the pro-inflammatory cytokine response.
To determine the pro-inflammatory signaling pathway controlled by IRGM, we performed a time-course experiment of LPS treatment in control and IRGM-depleted THP-1 cells. As compared to the control cells, the IRGM-depleted cells have lesser IkBa that was degraded faster with LPS treatment ( Figure 1K ). In the agreement, phospho-NF-kB-p65 levels were higher in IRGM-depleted cells at all the time points ( Figure 1K ). A previous study in mice indicated the role of p38 MAPK signaling pathway in Irgm1-mediated LPS (TLR4) induced a pro-inflammatory cytokine response (Bafica et al., 2007) . Here, in human cells, we found a similar increase in phospho-p38 in IRGM knockdown cells compared to control cells ( Figure 1K ) suggesting that human IRGM inhibit both NF-kB and p38 MAPK pro-inflammatory signaling pathways to control pro-inflammatory cytokine response.
We note that our several attempts to generate an IRGM knockout human monocytic cell line or a colon epithelial cell lines by different CRISPR-CAS9 methods were unsuccessful. Consequently, in this study, we used siRNA (THP-1 and PBMCs) or small hairpin RNA (shRNA) (HT-29 cells) to transiently or stably knock down the human IRGM; typical knockdown efficiency in any given cell or cell line (PBMC, THP-1, HT-29) was found to be 40%-60% (Figures S1J-S1L).
IRGM Limits NLRP3 Inflammasome Activation
IL-1b is translated as pro-IL-1b that stays in inactivated form until a second signal activates inflammasomes leading to pro-IL-1b (E and F) HT-29 control and IRGM knockdown cells were infected with S. typhimurium (1:10 MOI, 8 hr), and the total RNA was subjected to qRT-PCR with (E) IL-1b and (F) TNF-a. (G-J) The total RNA isolated from the LPS-stimulated (100 ng/mL, 2 hr) control and IRGM siRNA-transfected (G and H) THP-1 cells or (I and J) PBMCs from five healthy donors were subjected to qRT-PCR for the indicated genes. For (G) and (H), n = 3, mean ± SE, *p < 0.05, Student's unpaired t test. For (I) and (J), n = 5, mean ± SE, *p < 0.05, Student's paired t test. (K) The LPS (500 ng/mL)-stimulated control and IRGM siRNA-transfected THP-1 cell lysates were subjected to immunoblotting with indicated antibodies. (L) The supernatants from control and IRGM siRNA-transfected THP-1 cells, which were stimulated with LPS (100 ng/mL, 4 hr) alone or in combination with nigericin (5 mM, 30 min), were subjected to ELISA with IL-1b antibody. (M and N) The western blotting was performed with control and IRGM siRNA-transfected THP-1 cells, which were stimulated with LPS (1 mg/mL for 3 hr) alone or in combination (M) with nigericin (5 mM, 30 min) or (N) with ATP (2.5 mM, 4 hr).
(O and P) Quantification of (O) active caspase-1 (FLICA assay) and (P) secreted IL-1b (ELISA) in THP-1 cells transfected with control, IRGM, and NLRP3 siRNA and treated with LPS (1 mg/mL, 3 hr) and nigericin (5 mM, 15 min). (Q) The control and IRGM siRNA-transfected THP-1 cells were treated with LPS (1 mg/mL, 3 hr), nigericin (5 mM, 15 min), or MCC950 (1 mM) as indicated, and western blotting was performed. Unless otherwise stated above, n = 3, mean ± SD, *p < 0.05, **p < 0.005, ***p < 0.0005, # insignificant, Student's unpaired t test. See also Figure S1 . cleavage by caspase-1 to a mature form that is secreted (Choi and Ryter, 2014) . We next investigated whether IRGM controls the levels of secreted IL-1b. In ELISA assays, the secreted IL-1b levels were significantly increased on silencing IRGM (Figure 1L) indicating that IRGM suppresses IL-1b cleavage and secretion. The treatment of THP-1 cells with LPS and the inflammasome inducers nigericin ( Figure 1M ) or ATP ( Figure 1N ) resulted in increased cleavage of caspase-1 and IL-1b in IRGM-depleted cells compared to the control cells. The results indicate that IRGM suppresses the cleavage of caspase-1 and IL-1b presumably by suppressing NLRP3 inflammasome. We validated this notion by depleting (by siRNA) and inhibiting (by MCC950) the NLRP3 in IRGM knockdown cells. The enhanced inflammasome activation in IRGM-depleted THP-1 cells was blunted when NLRP3 was depleted or inhibited and S1M) suggesting that IRGM inhibits NLRP3 activity to suppress activation of caspase-1 and IL-1b.
IRGM Interacts and Co-localizes with NLRP3 and ASC over the Inflammasomes
Several diverse signals can activate NLRP3 leading to the oligomerization of NLRP3, the adaptor protein ASC, and the caspase-1 enzyme for the assembly of an activated inflammasome (Choi and Ryter, 2014) . Since we found that IRGM suppresses cleavage of caspase-1 and IL-1b, next, we examined the mechanism by which IRGM suppresses the activity of NLRP3 inflammasome. First, we investigated whether IRGM physically associates with inflammasome components. In immunoprecipitation assays, IRGM strongly interacted with both exogenous and endogenous NLRP3 ( Figures 2A-2C and S1N). The endogenous IRGM and NLRP3 interacted in THP-1 monocytes ( Figure 2C ), and the interaction was increased in the presence of Salmonella typhimurium ( Figure S1N ). Endogenous as well as exogenously expressed IRGM was found to be completely co-localized with the NLRP3 in the perinuclear regions of the cells (Figures 2D, S1O, and S1P). In GST pulldown assays, purified IRGM directly interacted with NLRP3 in a concentration-dependent manner ( Figure 2E ). Taken together, the data suggest that IRGM directly interacts and co-localizes with NLRP3.
On inflammasome activation, ASC oligomerizes with itself and with NLRP3 and caspase-1 to form an active inflammasome complex. In immunoprecipitation assays, performed in THP-1 cells, IRGM interacted with ASC, both under basal and inflammasome-inducing conditions ( Figure 2F ). ASC formed distinct specks in the cells that are hallmarks of inflammasome activation. Under inflammasome-inducing conditions, IRGM co-local-ized with ASC and NLRP3 in the core region of specks (Figures 2G, S1Q, and S1R). In co-immunoprecipitation (coIP) experiments, IRGM interacted with ASC, and this interaction was increased when NLRP3 was co-expressed ( Figure 2H ). In agreement with this, the co-localization of overexpressed ASC structures and IRGM was dramatically increased when NLRP3 was co-expressed ( Figures 2I-2K ). Also, the depletion of NLRP3 reduced the ASC-IRGM interaction ( Figure 2L ). The data show that NLRP3 is important for bridging IRGM and ASC. Next, in a domain-mapping experiment, we found that IRGM interacts with PYRIN domain but not with the CARD domain of ASC (Figures 2M and 2N) . The PYRIN is the oligomerization domain of ASC. Taken together, the data suggest that IRGM is part of NLRP3 inflammasome where it complexes with both NLRP3 and ASC.
IRGM Interferes with NLRP3 Inflammasome Assembly
To further understand the details of the NLRP3-IRGM interaction, we mapped the binding of IRGM to functional domains in NLRP3 ( Figure 3A ). NLRP3 is composed of PYRIN, NACHT (nucleotide binding domain or NBD), and LRR domains (Figure 3A) . We found that IRGM predominantly interacted with the NACHT domain ( Figure 3A) . A weak interaction with LRR and almost negligible interaction with PYRIN domain were observed ( Figure 3A ). The NACHT domain of NLRP3 is an ATP binding domain with an ATPase activity (Duncan et al., 2007) . An intact NACHT domain of NLRP3 is required for its oligomerization and activation (Duncan et al., 2007) . Hence, we examined whether IRGM perturbs the oligomerization of NLRP3. Indeed, in crosslinking experiments, IRGM depletion was sufficient to increase oligomerization of NLRP3 ( Figure 3B ). In contrast, the oligomeric forms of overexpressed NLRP3 were reduced when IRGM was overexpressed ( Figure 3C ). Further, in coIP assays, IRGM was able to reduce homotypic interaction between FLAG-NLRP3 and GFP-NLRP3 ( Figure 3D ). Furthermore, overexpression of IRGM reduced the interaction between full-length NLRP3 and NACHT domain ( Figure 3E ) and also between FLAG-NACHT and mCherry-NACHT suggesting that IRGM disrupts the homo-oligomerization of the NLRP3 ( Figure 3F ). In immunofluorescence assays, the size of NLRP3 aggregates was reduced in the presence of IRGM ( Figures S2A-S2C ). Altogether, the data show that IRGM restricts the oligomerization of NLRP3.
ASC possess prion-like properties of self-association and forms branched fiber-like structure important for inflammasome activation (Cai et al., 2014) . A high-resolution microscopy of ASC specks in THP-1 cells revealed a significantly larger and branched ASC specks in IRGM knockdown cells compared to (D) Representative confocal images of THP-1 macrophages, treated with LPS and processed for immunofluorescence (IF) analysis. (E) GST pull-down assay of in-vitro-translated and radiolabeled myc-tagged NLRP3 with GST or GST-tagged IRGM. (F) IP analysis of interaction between endogenous IRGM and ASC in LPS+nigericin-treated THP-1 cells. (G) Representative confocal images of THP-1 cells, treated with LPS (1 mg/mL, 3 hr) and nigericin (5 mM, 30 min) and processed for IF analysis. the control cells ( Figures 3G and 3H) . In contrast, when IRGM was overexpressed, ASC specks were found to be significantly smaller in overexpressing cells compared to the control cells ( Figures S2D-2F ). The data indicate that IRGM suppresses the polymerization of ASC. To corroborate these findings, we performed biochemical assays. In coIP experiments, the overexpression of IRGM reduced interaction between HA-ASC and FLAG-ASC ( Figure 3I ). In western blotting experiments performed with cross-linked insoluble cellular fraction, ASC oligomerization was inhibited by overexpression of IRGM (Figure S2G) . In contrast, the amount of oligomerized ASC in the insoluble fraction of the THP-1 cells was markedly increased in IRGM knockdown cells compared to the control cells ( Figure 3J ). Taken together, these results suggest that IRGM obstructs the oligomerization of ASC also. The interaction between NLRP3 and ASC was also reduced in the presence of IRGM ( Figure 3K , see also Figure 5E ), but the interaction between ASC and caspase-1 was unaffected by IRGM ( Figure S2H ). Overall, we found that IRGM restricts assembly of the inflammasome by impeding the homo-and hetero-oligomerization of NLRP3 and ASC.
IRGM Mediates Autophagic Degradation of NLRP3 Inflammasome Components
We found that the overexpression of IRGM reduced NLRP3 levels ( Figure 4A , S2I, and S2J), while silencing IRGM by siRNA increased the total amount of endogenous NLRP3 ( Figures 4B  and S2K ). The data indicate that IRGM mediates degradation of the NLRP3 protein.
NLRP3 is known to be degraded by both the proteasome and autophagy Song et al., 2016) . The Bafilomycin A1 (BafA1, an autophagy inhibitor), but not MG132 (a proteasome inhibitor), was able to restore the IRGM-mediated degradation of NLRP3 indicating a role for autophagy in the degradation process ( Figures 4C and S2L ). In the absence of the essential autophagy proteins, ATG5 or ATG7, IRGM was not able to degrade NLRP3 (Figures 4D-4G and S2M) suggesting that IRGM degrades NLRP3 via autophagy process.
ASC as a part of an inflammasome was previously shown to be degraded by autophagy (Shi et al., 2012) . Here, we found that overexpression of IRGM reduced ASC protein levels ( Figures  4H and S2N ), while IRGM depletion resulted in increased ASC amounts ( Figures 4I and S2O ). This finding was further supported by immunofluorescence experiments showing that the LPS and nigericin-induced ASC specks (inflammasomes) were significantly increased in number on knocking down IRGM ( Figures  S2P and S2Q) . In contrast, overexpression of IRGM significantly reduced the total number of ASC specks ( Figures S2R and S2S) . These data suggest that IRGM mediates degradation of ASC. This degradation was completely restored in the presence of BafA1, but only partly in the presence of MG132 ( Figures 4J  and S2T ). In the absence of ATG5 or ATG7, IRGM was not able to degrade ASC ( Figures 4F and 4G ) suggesting that IRGM degrades ASC via autophagy process.
IRGM Mediates p62-Dependent Selective Autophagy of NLRP3 Inflammasomes p62 is a selective autophagy adaptor protein that plays a vital role in autophagic degradation of several inflammatory signaling pathway proteins including inflammasomes and their components (Chen et al., 2016; Samie et al., 2018; Shi et al., 2012) . Here, we explored whether IRGM acts as a scaffold protein to mediate p62-dependent selective autophagy of NLRP3. We found that IRGM interacted and co-localized with p62 ( Figures  4K and 4L ). IRGM was also required for expression of p62 under basal and inflammasome-inducing conditions in THP-1 cells ( Figure S3A ). NLRP3 itself can interact and co-localize with p62 ( Figures S3B-3D ). In THP-1 cells, p62 was co-localized with NLRP3 ( Figure S3D ) on perinuclear structures that appeared similar to those on which IRGM and NLRP3 co-localized ( Figure 2D ) suggesting that all the three proteins are part of the same complex. In HEK293T cells, overexpressed IRGM, p62, and NLRP3 co-localized with each other suggesting that they are indeed in a single complex ( Figure 4M ). IRGM increased the interaction of p62 with both NLRP3 (Figures 4N and 4O ) and ASC ( Figure 4P ) suggesting that IRGM is vital for bridging p62 with NLRP3-and ASC-containing inflammasomes.
Next, we asked whether p62 as a part of the IRGM-p62-NLRP3 complex is required for IRGM-mediated autophagic degradation of NLRP3. Indeed, depletion of p62 by siRNA restored IRGM-mediated NLRP3 degradation (Figures 4Q and S3E) . ULK1 plays an important role in autophagy initiation, whereas Beclin1 and ATG16L1 are required for autophagosome assembly and elongation. Since IRGM interacts with ULK1, Beclin 1, and ATG16L1 for assembly of the autophagy (K) IP analysis of interaction between NLRP3 and ASC in the absence and presence of GFP-IRGM. *In order to reduce the artifact coming from IRGM-mediated degradation of NLRP3 and ASC, the inputs ratios were adjusted to have equal inputs in both the conditions and the IP samples were run in the same ratios as of the inputs. Scale bars are as indicated in figures. See also Figure S2 . machinery , we next asked which of these autophagy proteins are utilized by IRGM for autophagy of NLRP3. NLRP3 and IRGM co-localized with all three autophagy regulatory proteins (Figures 4R, S3F, and S3G ). Further, in coIP experiments, IRGM robustly increased NLRP3-Beclin1 and NLRP3-ATG16L1 interactions ( Figures 4S and S3H ) but did not affect NLRP3-ULK1 interaction ( Figure S3I ). Taken together, the data suggested a scaffolding role for IRGM in bringing the autophagy adaptor protein (p62), autophagy initiation (Beclin 1), and elongation protein (ATG16L1) over the NLRP3 inflammasomes. We performed time-chase immunofluorescence experiments to understand whether the p62 docks to NLRP3/ASC complex first or the Beclin1/ATG16L1 reaches the complex first. The IRGM-p62-ASC showed co-localization in 5 min of stimulation, whereas ATG16L1 came later at 15 min or more prominently on 30 min post stimulation ( Figures S4A and S4B) . We also performed time-chase immunofluorescence experiments in overexpression system in HEK293T cells. The data show that, in the presence of p62, the NLRP3-IRGM puncta formation are fast, and all three p62, IRGM, and NLRP3 co-localized with each other 6 hr posttransfection ( Figures S4C and S4D) , whereas in the presence of Beclin1 the IRGM-NLRP3 complex appeared at 12 hr post-transfection ( Figures S4C and S4D) . Taken together, the data suggest that p62 being an adaptor protein recognizes the inflammasome first followed by docking of other autophagy proteins.
NLRC4 and AIM2 are other well-studied inflammasomes. The NLRC4 levels were unchanged, whereas, surprisingly, AIM2 levels were decreased on knocking down IRGM ( Figures  5A and 5B) . However, the overexpression of IRGM did not significantly affect the levels of overexpressed AIM2 in HEK293T (Figures S5C and S5D) suggesting that the reduction in AIM2 expression observed in IRGM knockdown THP-1 cells is not a direct effect of IRGM low expression but could be a secondary event. This notion is supported by negligible AIM2-IRGM co-localization ( Figures S5E and S5F ). Taken together, our data show that AIM2 or NLRC4 are not degraded by IRGM-mediated selective autophagy, and the discovered mechanism is specific to NLRP3.
Next, we investigated whether the LPS and inflammasome activator-induced general autophagy flux is controlled by IRGM. The results suggest that LPS-, LPS+nigericin-, and LPS+ ATP-induced autophagy flux is inhibited upon IRGM depletion ( Figures 5A and 5B) , whereas the LPS+poly(dA-dT) (an AIM2 inflammasome inducer)-induced autophagy flux was not affected by knockdown of IRGM ( Figure S5G ).
IRGM mediates selective autophagy of NLRP3 and ASC and also regulates basal autophagy. We asked whether IRGM itself is an autophagy target. In cycloheximide chase experiments, we found that MG132 but not BafA1 could protect IRGM from degradation suggesting that IRGM is degraded by proteasome but not by the autophagy (Figures S5H and S5I) .
Two Distinct Mechanisms Governed by IRGM Regulate NLRP3 Inflammasome Suppression
IRGM utilizes two mechanisms: (1) suppression of oligomerization and (2) autophagic degradation of NLRP3/ASC to inhibit the inflammasome activation. Next, we performed experiments to determine whether these two mechanisms are distinct or dependent on each other. In oligomerization assays, in the presence of autophagy inhibitor chloroquine, although the IRGMmediated degradation of NLRP3 and ASC monomers (soluble fraction) was significantly restored, the oligomerization defect of NLRP3 and ASC was not rescued (Figures 5C and 5D ). These data indicate that the IRGM-mediated autophagic degradation of NLRP3 and ASC is independent of IRGM-regulated inhibition of oligomerization. Next, we found that IRGM was able to inhibit the oligomerization of NLRP3, as well as ASC even in the presence of autophagy inhibitor ( Figures 5E and 5F) suggesting that IRGM-mediated oligomerization defect is independent of IRGM-controlled autophagic degradation of NLRP3 and ASC.
A recent study showed that a single mutation in the GTPase domain (S47N) of IRGM makes it incompetent in interaction with Syntaxin 17, an autophagosome-lysosome fusion protein (Kumar et al., 2018) . We found that this mutation (S47N, IRGM GTPase activity defective) in IRGM renders it inefficient in degrading NLRP3 suggesting the importance of IRGM GTPase activity in autophagy-mediated cargo degradation ( Figure S5J ). Very interestingly, this mutation was able to rescue the IRGMmediated autophagic degradation of NLRP3 but not the oligomerization defect mediated by IRGM ( Figure S5J) . Taken together, the results suggest that IRGM controls two distinct mechanisms, autophagic degradation of NLRP3 (GTPasedependent function) and inhibition of oligomerization of NLRP3 (GTPase-independent function).
Next, we performed several experiments to parse out the relative contribution of these two mechanisms in inhibiting NLRP3 inflammasome activation. We observed that the treatment of 3-MA (an autophagy inhibitor) results in increased inflammasomes (ASC specks) numbers and IL-1b secretion compared to the untreated THP-1 cells suggesting that autophagy reduces the NLRP3 inflammasome formation and activation (Figures 5G and 5H and S5K) . We found that knockdown of IRGM induces significantly more ASC specks formation and also IL-1b secretion as compared to the 3-MA-treated THP-1 cells (Figures 5G  and 5H) . These data indicate that IRGM-mediated suppression of inflammasomes includes mechanisms more than autophagy-mediated degradation. The 3-MA-treated IRGM knockdown cells showed significantly higher ASC speck formation and IL-1b secretion than 3-MA-treated control cells ( Figures  5G and 5H) suggesting that, in addition to autophagy-mediated suppression, the IRGM-mediated inhibition of oligomerization of inflammasomes may play a significant role in suppressing NLRP3 inflammasomes. Similar results were obtained when selective autophagic degradation of inflammasome was inhibited by knocking down of p62 in IRGM-depleted THP-1 cells ( Figures  5I and 5J ). Next, in HEK293T inflammasome reconstitution system, the overexpression of IRGM reduces caspase-1 cleavage ( Figures 5K and 5L cf. lane 1 and 2 in SE) and also the IL-1b secretion ( Figure 5M ). The inhibition of autophagy (using chloroquine or ATG5 knockdown) in IRGM-overexpressing cells increased the caspase-1 cleavage and also IL-1b secretion but to lesser extent than autophagy-inhibited control cells ( Figures  5K and 5L , cf. lane 4 with 3 in long exposure [L.E.], Figure 5M ) suggesting yet again that IRGM mediates suppression of NLRP3 inflammasome by at least two distinct mechanisms discovered here.
IRGM Protects from Pyroptosis
Pyroptosis is an inflammatory cell death mediated by activation of inflammasomes (also called pyroptosomes) (Fernandes-Alnemri et al., 2007; Shi et al., 2017) . Annexin V and propidium iodide (PI) double staining was used to access the role of IRGM in pyroptosis. Due to the formation of pores, pyroptotic cells are mainly stained by PI (PI is cell membrane impermeant). Annexin-V cannot distinguish between apoptotic cells and pyroptotic cells and stains both of them. In flow cytometry experiments, on exposure of inflammatory threats, both the apoptotic and pyroptotic populations were increased considerably in IRGM-depleted THP-1 cells compared to control cells ( Figures  6A-6G, S6A, and S6B) . These results suggest that IRGM protects the cells from inflammation-induced cell death. In the lactate dehydrogenase (LDH) release assays, there was a significant increase in the LDH amount in supernatant collected from LPS-and DAMP-treated IRGM-depleted THP-1 cells compared to the control cells ( Figure S6C ). Similar results were obtained using a trypan blue exclusion assay that accesses the integrity of the cell membrane during cell death ( Figure S6D ).
Recent studies identified Gasdermin D (GSDMD) as an effector protein for pyroptosis Shi et al., 2015) . In agreement with caspase-1 cleavage data presented in Figure 1 , the cleavage of GSDMD was increased in IRGM-depleted cells compared to the control cells ( Figure 6H ). In agreement with flow cytometry data, apoptosis was also increased in IRGM knockdown cells compared to control cells as clear from the enhanced PARP1 (Poly [ADP-ribose] polymerase 1) cleavage ( Figure 6I ). Taken together, our data show that IRGM protects cells from inflammation-induced cell death.
Next, we blocked the caspase's activity using the pan-caspase inhibitor z-VAD-FMK or selective caspase-1 inhibitor Ac-YVAD-CMK to determine whether the inflammatory cell death observed in IRGM-depleted cells is caspase dependent or independent. The results (both by flow cytometry and western blotting) show that z-VAD-FMK and Ac-YVAD-CMK can block pyroptosis and also can reduce apoptosis induced by IRGM depletion (Figures 6J-6N) suggesting that IRGM suppresses caspase-1-dependent inflammatory cell death.
Mouse Irgm1 Suppresses the Gut Inflammation by Inhibiting the NLRP3 Inflammasome Activation
Although human IRGM and mouse Irgm1 possess biochemical differences, they have been found to have overlapping functions, (legend on next page) particularly as related to innate immunity and autophagy. Given the role of IRGM in inflammatory bowel disease (IBD) and Crohn's, we utilized the dextran-sulfate (DSS)-induced colitis model to investigate the role of Irgm1 in Nlrp3 inflammasome activation. Irgm1 À/À mice have previously been shown to exhibit enhanced inflammation following DSS administration (Liu et al., 2013) . Consistent with this report, we found here that the administration of DSS led to decreased body weight and colon length in Irgm1 À/À mice relative to those responses in littermate Irgm1 +/+ mice (Figures S7A-S7D ). Like in human colon cells, the expression of IL-1b, TNF-a, and IL-18 was significantly increased in DSS-treated Irgm1 À/À compared to Irgm1 +/+ mice ( Figure 7A ). Next, we scrutinized the expression of inflammasome components. In untreated mice, Nlrp3 expression was increased in Irgm1 À/À mice compared to Irgm1 +/+ mice (Figure 7B) ; however, expression of ASC was not different (Figure 7B) . In DSS-treated mice, the expression of both Nlrp3 and ASC in bone-marrow-derived macrophages and colon was more in Irgm1 À/À mice compared to Irgm1 +/+ mice (Figures 7C and 7D) . Also, ASC oligomerization was considerably higher in Irgm1 À/À mice compared to Irgm1 +/+ mice ( Figures 7C and  7D ). In a cross-linking experiment with bone marrow-derived macrophages (BMDMs), both ASC and Nlrp3 oligomerization was found to be increased in Irgm1 À/À mice compared Irgm1 +/+ mice (Figures 7E and S7E; STAR Methods) . Under inflammasome-inducing conditions, the active caspase-1 amount was significantly higher in Irgm1 À/À mice compared to control Irgm1 +/+ mice ( Figure 7F ). Similar to human cell lines studies, the basal autophagy and also the LPS-induced autophagy flux in BMDMs were dependent on the expression of Irgm1 (Figure 7G) . Altogether, the data show that Irgm1, like its human ortholog, suppresses the activation of the NLRP3 inflammasome by inhibiting its assembly and by increasing autophagy.
Next, we analyzed whether increased Nlrp3 inflammasome activation is the cause for exacerbated outcomes of DSSinduced colitis in Irgm1 knockout mice. MCC950 is the most potent and the most specific small-molecule inhibitor of activation of NLRP3 known to date (Coll et al., 2015; Strangward et al., 2018; Yao et al., 2018) . We investigated whether selective pharmacologic blockade of the Nlrp3 inflammasome using MCC950 would reduce the colitis symptoms in Irgm1 À/À mice. Indeed, we found that all the intensified outcomes of DSSinduced colitis in the Irgm1 knockout mice were reversed in the presence of MCC950 ( Figures 7H-7J, S7F, and S7G) . At molecular levels, in colon tissues, the increased amount of inflammasome components (Nlrp3, ASC monomers, and dimers) and also the enhanced inflammasome activity as measured by cleaved caspase-1 by western blot ( Figure 7K ) and fluorescent caspase-1 cleavage assay ( Figure 7L ) in Irgm1 À/À mice were reversed by MCC950 treatment. Next, we isolated the BMDMs from these mice and induced the inflammasome (using LPS+ nigericin) in the absence and presence of MCC950. Again, the data show that inactivation of Nlrp3 by MCC950 considerably reduced the enhanced inflammasome activity in Irgm1 À/À mice as measured by fluorescent caspase-1 cleavage assay (Figure 7M ) and western blotting (Nlrp3, ASC dimer, and caspase-1 cleavage) ( Figure 7N ). Next, we used a genetic approach to determine whether enhanced inflammasome activation in Irgm1 À/À mice BMDMs is because of increased activation of the Nlrp3/ASC inflammasome. In LPS+nigericin-stimulated BMDMs, the increased caspase-1 cleavage (Figures 7O and  S7H ) and the IL-1b secretion (Figures 7P and S7H) in Irgm1 À/À mice BMDMs was blunted when Nlrp3 was depleted in these cells using siRNA.
Taken together, several lines of evidence suggest that NLRP3 activation is the primary factor behind enhanced inflammasome activity in IRGM-depleted cells, and also the activation of NLRP3 inflammasome is one of the major reasons for exacerbated outcomes of DSS-induced colitis in the Irgm1 knockout mice. We conclude that the IRGM/Irgm1 suppresses the NLRP3 inflammasome to keep the gut inflammation under check.
DISCUSSION
In landmark genome-wide association studies conducted by Wellcome Trust Case Control Consortium to understand the genetic determinants of inflammatory diseases, SNPs in the IRGM locus were found to be strongly associated with Crohn's disease (Wellcome Trust Case Control, 2007; Craddock et al., 2010) . Later, several studies showed similar genetic linkages of IRGM with Crohn's disease and other inflammatory and autoimmune diseases in different populations worldwide (Baskaran et al., 2014; Glas et al., 2013; Li et al., 2014; McCarroll et al., 2008; Xia et al., 2017; Yang et al., 2014) . Most of these studies suggested a protective role of IRGM against the 
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Irgm1 (legend continued on next page) inflammatory diseases; however, none of the studies revealed the mechanism(s).
Irgm1
This study defined the mechanism by which IRGM/Irgm1 regulates cellular inflammation in immune and gut epithelial cells ( Figure S7I ). We found here that IRGM suppresses IL-1b production by limiting the activation of the NLRP3 inflammasome ( Figure S7I ). Remarkably, IRGM performs this function by complexing directly with inflammasome components including NLRP3 and ASC. By binding to the oligomerization domain (NACHT) of NLRP3, it impedes the oligomerization of NLRP3. IRGM also hinders polymerization of ASC protein ( Figure S7I ), which is a key event for activation of inflammasome (Cai et al., 2014; Lu et al., 2014) . Previous studies demonstrated the role of autophagy process in limiting the IL-1b production, and one of the mechanisms was by degrading the inflammasome and its components in a p62dependent manner (Shi et al., 2012) . Here, we found that IRGM is a key player in mediating p62-dependent selective autophagy of NLRP3 and ASC ( Figure S7I ). Thus, IRGM limits IL-1b production by two mechanisms: (1) by interfering in the assembly of the inflammasome and (2) by mediating autophagy of inflammasome. In the inflammatory bowel disease experimental mice model, Irgm1 suppresses the colitis by inhibiting the NLRP3 inflammasome. Taken together, this work revealed IRGM-mediated anti-inflammatory immune homeostasis mechanism by which IRGM could be protective against inflammatory diseases.
As compared to humans, where IRGM is a lone member of the IRG family, mice have 20 more homologs of Irgm1, presumably providing the compensation when the Irgm1 is knockout in the mice. Although human IRGM and mice Irgm1 are of different size (21 versus 47 kDa), they are strikingly similar in the regulation of autophagy and inflammation.
The dysregulated NLRP3 inflammasome has been linked to the pathogenesis of several inflammatory diseases including gout, type 2 diabetes, cancer, cardiovascular diseases, Alzheimer's, Parkinson's, and prion diseases (Alcocer-Gó mez and Cordero, 2017; Lee et al., 2013; Song et al., 2017) . Also, mutations in the NLRP3 gene have been linked with a range of dominantly inherited auto-inflammatory diseases (Masters et al., 2009) . Therefore, it is of high importance to the medical science to understand the mechanisms by which the cell restrains the activation of NLRP3 inflammasome and IL-1b production. For similar reasons, understanding the protective nature of IRGM in human inflammatory diseases is crucial. This study delineates both. The therapeutic strategies to increase IRGM activity or targeting the IRGM-NLRP3 interaction could be useful for treating IRGM-and NLRP3-associated diseases.
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STAR+METHODS
Isolation of human peripheral blood mononuclear cells (PBMCs)
Isolation of Human PBMCs were performed using density gradient centrifugation method using Histopaque as per manufacture recommendations (Sigma). Briefly, 5 mL homogenized blood were mixed with an equal volume of PBS and slowly layered on the 3 mL Histopaque-1077 (Sigma 1077, density 1.077). The sample was then centrifuged at 400 g for 20 minutes at room temperature (RT) using slow acceleration and deceleration. Buffy coat generated in the middle of the gradient was collected, mixed with DPBS and spun at 100 g for 10 minutes. Cells were then washed twice with DPBS and re-suspended in RPMI-1640 supplemented with 10% FBS and incubated at 37 C with 5% CO 2 overnight. Cells were counted in an Invitrogen Countless II Automated Cell Counter using an equal volume of trypan blue (Sigma). A total of 2 3 10 6 cells were seeded in each 6 well plate for treatment with LPS (100 ng/ml). Total RNA was extracted using TRIZOL (Invitrogen).
Plasmid Constructs and Transfection
The mcherry-IRGM and Flag-NLRP3 and its deletion constructs were generated using gateway cloning strategy as per standard protocols (Invitrogen).
Transient transfection with siRNA
The THP-1 and PBMC cells were electroporated (Neon, Invitrogen; setting: 1400V, 10ms, 3 pulse using the 100 ml tip) with non-targeting siRNA (30nM) or IRGM siRNA (30nM) or p62 siRNA (30nM) or ATG5 siRNA ((30nM) or ATG7 siRNA ((30nM) and incubated for 24h. After 24h, one more time transfection was performed in similar condition as described above and incubated for another 48 h before start of each experiment. The HT-29 cells and HEK293T cells were transfected with 10 nM siRNA using LipofectamineÒ RNAiMAX Transfection Reagent as per manufacturer's instructions. For transient gene/s knockdown experiment in BMDMs: Freshly isolated, 4x10 6 Bone marrow cells electroporated with non-targeting siRNA or NLRP3 siRNA (30nM) using Neon system (Invitrogen) with following parameter: 1350V, 10 ms. 3 pulse and kept for 
